Literature DB >> 20534461

Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Marleen M van Loenen1, Renate de Boer, Avital L Amir, Renate S Hagedoorn, Gerdien L Volbeda, Roelof Willemze, Johannes J van Rood, J H Frederik Falkenburg, Mirjam H M Heemskerk.   

Abstract

Adoptive transfer of T cell receptor (TCR)-transduced T cells may be an attractive strategy to target both hematological malignancies and solid tumors. By introducing a TCR, large numbers of T cells with defined antigen (Ag) specificity can be obtained. However, by introduction of a TCR, mixed TCR dimers can be formed. Besides the decrease in TCR expression of the introduced and endogenous TCR, these mixed TCR dimers could harbor potentially harmful specificities. In this study, we demonstrate that introduction of TCRs resulted in formation of neoreactive mixed TCR dimers, composed of the introduced TCR chains pairing with either the endogenous TCR alpha or beta chain. Neoreactivities observed were HLA class I or class II restricted. Most neoreactive mixed TCR dimers were allo-HLA reactive; however, neoreactive mixed TCR dimers with autoreactive activity were also observed. We demonstrate that inclusion of an extra disulfide bond between the constant domains of the introduced TCR markedly reduced neoreactivity, whereas enhanced effectiveness of the introduced TCR was observed. In conclusion, TCR transfer results in the formation of neoreactive mixed TCR dimers with the potential to generate off-target effects, underlining the importance of searching for techniques to facilitate preferential pairing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534461      PMCID: PMC2890759          DOI: 10.1073/pnas.1005802107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population.

Authors:  Inge Jedema; Nicole M van der Werff; Renée M Y Barge; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

3.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

Authors:  H J Kolb; J Mittermüller; C Clemm; E Holler; G Ledderose; G Brehm; M Heim; W Wilmanns
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

4.  Transfer of specificity by murine alpha and beta T-cell receptor genes.

Authors:  Z Dembić; W Haas; S Weiss; J McCubrey; H Kiefer; H von Boehmer; M Steinmetz
Journal:  Nature       Date:  1986 Mar 20-26       Impact factor: 49.962

5.  Immunotherapy through TCR gene transfer.

Authors:  H W Kessels; M C Wolkers; M D van den Boom; M A van der Valk; T N Schumacher
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

6.  Allo-HLA reactivity of virus-specific memory T cells is common.

Authors:  Avital L Amir; Lloyd J A D'Orsogna; Dave L Roelen; Marleen M van Loenen; Renate S Hagedoorn; Renate de Boer; Menno A W G van der Hoorn; Michel G D Kester; Ilias I N Doxiadis; J H Frederik Falkenburg; Frans H J Claas; Mirjam H M Heemskerk
Journal:  Blood       Date:  2010-02-16       Impact factor: 22.113

7.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Roelof A de Paus; Michel G D Kester; Menno A W G van der Hoorn; Els Goulmy; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

Review 8.  T-cell-receptor gene therapy.

Authors:  Ton N M Schumacher
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

9.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

10.  Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

View more
  113 in total

1.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 2.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

3.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

Review 4.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

Review 5.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 8.  Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.

Authors:  S D Sackett; M E Brown; D M Tremmel; T Ellis; W J Burlingham; J S Odorico
Journal:  Transplant Rev (Orlando)       Date:  2016-02-10       Impact factor: 3.943

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

10.  Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Authors:  Arnab Ghosh; Yildirim Dogan; Maxim Moroz; Amanda M Holland; Nury L Yim; Uttam K Rao; Lauren F Young; Daniel Tannenbaum; Durva Masih; Enrico Velardi; Jennifer J Tsai; Robert R Jenq; Olaf Penack; Alan M Hanash; Odette M Smith; Kelly Piersanti; Cecilia Lezcano; George F Murphy; Chen Liu; M Lia Palomba; Martin G Sauer; Michel Sadelain; Vladimir Ponomarev; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.